Picture of Celyad Oncology SA logo

CYAD Celyad Oncology SA Share Price

0.000.00%
be flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapSucker Stock

Momentum

Relative Strength (%)
1m-4.5%
3m-8.35%
6m-57.27%
1yr-63.16%
Volume Change (%)
10d/3m-82.12%
Price vs... (%)
52w High-72.27%
50d MA-4.76%
200d MA-31.03%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)n/a
PEG Ratio (f)n/a
EPS Growth (f)n/a
Dividend Yield (f)n/a
Valuation (ttm)IndustryMarket
Price to Book Value14.43
Price to Tang. Book39.32
Price to Free Cashflown/a
Price to Sales334.25
EV to EBITDAn/a

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-501.56%
Return on Equity-193.37%
Operating Margin-69375%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202331st Dec 2024
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2023 / 2024

Blurred out image of Celyad Oncology SA EPS forecast chart

Profile Summary

Celyad Oncology SA, formerly Celyad SA is a Belgium-based company. The Company is a clinical-stage biotechnology company focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The Company develops allogeneic and autologous CAR T cell therapy candidates for cancer patients with hematological malignancies and solid tumors. The Company's product, CYAD-101 is a NKG2D receptor-based CAR T, which incorporates non-gene edited allogeneic TIM technology, for the treatment of refractory metastatic colorectal cancer (mCRC). It also develops short hairpin RNA (shRNA)-based allogeneic CAR T candidate CYAD-211 for the treatment of relapsed or refractory multiple myeloma (r/r MM). Its autologous CAR T franchise is evaluating NKG2D receptor CAR T candidate CYAD-02 for the treatment of relapsed or refractory acute myeloid leukemia (r/r AML) and myelodysplastic syndromes (MDS).

Directors

Last Annual
December 31st, 2022
Last Interim
June 30th, 2023
Incorporated
July 24th, 2007
Public Since
July 5th, 2013
No. of Employees
28
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
be flag iconEuronext - Brussels
Shares in Issue
41,428,572
Blurred out image of a map
Address
Rue Andre Dumont 9, MONT-SAINT-GUIBERT, 1435
Web
https://www.celyad.com/
Phone
+32 10394100
Auditors
Ernst & Young Bedrijfsrevisoren BCV

CYAD Share Price Performance

Upcoming Events for CYAD

Full Year 2023 Celyad Oncology SA Earnings Release

Celyad Oncology SA Annual Shareholders Meeting

Q1 2024 Celyad Oncology SA Earnings Release

Celyad Oncology SA Annual Shareholders Meeting

Half Year 2024 Celyad Oncology SA Earnings Release

Similar to CYAD

Picture of argenx SE logo

argenx SE

be flag iconEuronext - Brussels

Picture of Oxurion NV logo

Oxurion NV

be flag iconEuronext - Brussels

Picture of Sequana Medical NV logo

Sequana Medical NV

be flag iconEuronext - Brussels

FAQ